2022 Annual Meeting of the European Association for the Study of the Liver*

Download All
June 22-26, 2022; London, United Kingdom
Get expert insights on key viral hepatitis data presented at EASL 2022 and learn how these data on HBV, HCV, and HDV may change your practice.
Tarik Asselah, MD, PhD
Nancy Reau, MD
Stefan Zeuzem, MD

ClinicalThought

Read my take on which new viral hepatitis data from EASL 2022 are the most practice changing, including HBV novel therapeutics in development, therapeutic vaccination for HBV cure, emerging treatments for HDV, HCV care cascade, and the need for HCC monitoring post HCV cure.

Nancy Reau, MD Released: July 13, 2022

Downloadable Slideset

Read expert faculty members’ summaries of HBV, hepatitis delta virus (HDV), and HCV, including data on investigational HBV agents, progress toward HBV cure, emerging treatments for HDV, and HCV treatment implementation in treatment-experienced patients.

Tarik Asselah, MD, PhD Stefan Zeuzem, MD Released: July 6, 2022

On-Demand Webcasts

Listen to expert insights on updates and new viral hepatitis data from EASL 2022, including data on investigational HBV agents, progress toward HBV cure, emerging treatments for HDV, HCV treatment implementation in treatment-experienced patients, and more.

Tarik Asselah, MD, PhD Released: July 8, 2022

Listen to expert insights on updates and new viral hepatitis data from EASL 2022, including data on investigational HBV agents, progress toward HBV cure, emerging treatments for HDV, HCV treatment implementation in treatment-experienced patients, and more.

Stefan Zeuzem, MD Released: July 6, 2022

Podcasts

Listen to expert insights from Stefan Zeuzem, MD, on updates and new viral hepatitis data from EASL 2022, including novel therapeutics for HBV, HBV cure data, therapeutic updates for HDV, and HCV treatment for treatment-experienced patients.

Stefan Zeuzem, MD Released: July 6, 2022

Listen to expert insights from Nancy Reau, MD, on updates and new viral hepatitis data from EASL 2022, including HBV novel therapeutics in development, therapeutic vaccination for HBV, emerging treatments for HDV, HCV care cascade, and the need for HCC monitoring post HCV cure.

Nancy Reau, MD Released: July 5, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings